<DOC>
	<DOCNO>NCT00845819</DOCNO>
	<brief_summary>The purpose study determine efficacy toxicity recombinant human epidermal growth factor ( rhEGF ) preventive drug oral mucositis intensive chemotherapy stem cell transplantation patient hematologic malignancy .</brief_summary>
	<brief_title>Study Epidermal Growth Factor Oral Mucositis Induced Intensive Chemotherapy Hematologic Malignancies</brief_title>
	<detailed_description>Oral mucositis one common adverse event chemotherapy affect quality life patient receive chemotherapy relation dose drug . However , one drug ( palifermin ) approve US FDA prevention oral mucositis method prevent treat oral mucositis empirical lack evidence . The result recent study demonstrate promising efficacy minimal toxicity recombinant human epidermal growth factor ( rhEGF ) preventive drug oral mucositis head neck cancer patient undergo radiotherapy ( Wu HG , et al . Cancer 2009 ; 115 ( 16 ) :3699-3708 ) . This clinical trial double-blind randomize prospective single-institutional phase II study evaluate efficacy toxicity recombinant human epidermal growth factor ( rhEGF ) preventive drug oral mucositis intensive chemotherapy stem cell transplantation patient hematologic malignancy .</detailed_description>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Povidone-Iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Nystatin</mesh_term>
	<mesh_term>Povidone</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Patients confirm diagnosis hematologic malignancy include acute &amp; chronic leukemia , lymphoma , plasma cell dyscrasia , myelodysplastic syndrome , aplastic anemia , etc . Patients plan receive highdose chemotherapy SCT ECOG performance status 02 Informed consent Patients previous history hypersensitivity drug similar drug Patients oral ulcer herpes severe dental disease time inclusion Patients receive chemotherapy , radiotherapy , surgery within 3 week Patients finish clinical trial could affect result trial within 4 week attend one time inclusion Patients another disease bad prognosis patient ' hematologic malignancy Patients major psychotic disorder drug/alcohol abuser Women pregnant breastfeeding Refusal patient ' Inappropriate patient accord investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>oral mucositis</keyword>
	<keyword>intensive chemotherapy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>epidermal growth factor</keyword>
</DOC>